Treatment With 25-Hydroxyvitamin D<sub>3</sub> (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-to-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With COVID-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial.

Endocr Pract · 2021 · PMC8511889 · PMID 34653608

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

COVID-19 Clinical Features There was an overall trend for lower hospitalization duration in the 25(OH)D 3 group compared with that in the placebo group, which was not statistically significant (median [IQR], 5 [3] vs. 6 [5.5]; P = .1).

also in 4,871 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.